NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Thousand Oaks Biopharmaceuticals

Thousand Oaks Biopharmaceuticals

Private
NantongHealthcare & Life Scienceshttps://tobiopharm.com/

Last Round

Series D

Dec 28, 2021

Est. Valuation

$1.33B

Total Funding Raised

$405.9M

Company Overview

Thousand Oaks Biopharmaceuticals is a biotechnology company that offers contract development and manufacturing organization (CDMO) services, enabling partners to provide accessible and affordable biologics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Pharma Supply Chain, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales

AI Layer

Application

Keywords

CRDMOCDMObiologics manufacturingmonoclonal antibodiesantibody-drug conjugatesADCchemistry manufacturing and controlsCMCGMP manufacturingcell line developmentbiotech outsourcingserum-free mediabispecific antibodiesdrug development servicesantibody discoverybiopharma supply chainin silico drug design

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Thousand Oaks Biopharmaceuticals Comparables

Compare Thousand Oaks Biopharmaceuticals with similar companies based on industry and business-model similarity.

Thousand Oaks Biopharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
WuXi Biologics
87%
Chime Biologics
86%
MabPlex International
85%

Thousand Oaks Biopharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DDec 28, 2021
Series CMar 10, 2021
Series BJul 23, 2020
Series AJan 3, 2019

Key People

Founding team and executive leadership

胡Alpha

Group CFO

Executive Team

Thousand Oaks Biopharmaceuticals Investors

Notable investors and investment history

Thousand Oaks Biopharmaceuticals investors
InvestorRounds
HighLight CapitalSeries C
New Alliance CapitalSeries A
CDH InvestmentsSeries C
CCIC CapitalSeries C
中信金石投资有限公司Series C, Series D, Series B
CDH BaifuSeries D
Hillhouse InvestmentSeries D, Series B, Series C

Thousand Oaks Biopharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Thousand Oaks Biopharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Thousand Oaks Biopharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersNantong
Employee Range46
Year Founded2017
Last FundingDec 28, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.